ERBB2 and breast carcinoma: Utilising immunohistochemistry and FISH, we retrospectively investigated the most likely parameters with immediate impact on HER2 activity and HerceptinTM responsiveness in a cohort of 48 HT breast cancer patients with HER2 amplification.